PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company

Oslo (Norway), 18 December 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over 6 months, until the end of June 2019, and may be further extended. The pharma company is one of the global leaders in nucleic acid therapeutics. The aim of the extension is to further evaluate the synergistic effects of both parties’ technology platforms and to determine whether PCI Biotech’s fimaNAc technology has the potential to enhance the therapeutic effect ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 7

Ähnlich Nachrichten